Literature DB >> 33662236

Avoiding Adverse Drug Withdrawal Events When Stopping Unnecessary Medications According to the STOPPFrail Criteria.

Joseph T Hanlon1, Jennifer Tjia2.   

Abstract

OBJECTIVE: To provide clinicians with information about avoiding adverse drug withdrawal events (ADWEs) when discontinuing unnecessary medications as per the STOPPFrail criteria. DATA SOURCES: Searches of MEDLINE (1970-June 2020), the Cochrane Database of Systematic Reviews (through June 2020), Google Scholar (through June 2020). STUDY SELECTION: Reviews and original studies of ADWEs. DATA EXTRACTION: Tapering protocols for specific drugs/ classes from randomized controlled deprescribing trials. DATA SYNTHESIS: Six drug classes were identified as being high risk for physiological ADWEs.
CONCLUSION: The occurrence of ADWEs is rare in comparison to adverse drug reactions in older adults. Few drugs/classes have been reported to have physiological ADWEs with abrupt discontinuation. For these we provide information about tapering protocols and symptom monitoring to avoid ADWEs.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33662236      PMCID: PMC8091161          DOI: 10.4140/TCP.n.2021.136

Source DB:  PubMed          Journal:  Sr Care Pharm        ISSN: 2639-9636


  36 in total

1.  Prevalence of potentially preventable unplanned hospitalizations caused by therapeutic failures and adverse drug withdrawal events among older veterans.

Authors:  Zachary A Marcum; Mary Jo V Pugh; Megan E Amuan; Sherrie L Aspinall; Steven M Handler; Christine M Ruby; Joseph T Hanlon
Journal:  J Gerontol A Biol Sci Med Sci       Date:  2012-03-01       Impact factor: 6.053

2.  The relationship of serum anticholinergic activity to mental status performance in an elderly nursing home population.

Authors:  G D Tollefson; J Montague-Clouse; S P Lancaster
Journal:  J Neuropsychiatry Clin Neurosci       Date:  1991       Impact factor: 2.198

3.  Drug discontinuation effects are part of the pharmacology of a drug.

Authors:  Marcus M Reidenberg
Journal:  J Pharmacol Exp Ther       Date:  2011-08-17       Impact factor: 4.030

Review 4.  Withdrawal reactions following cessation of central alpha-adrenergic receptor agonists.

Authors:  J L Reid; B C Campbell; C A Hamilton
Journal:  Hypertension       Date:  1984 Sep-Oct       Impact factor: 10.190

5.  Adrenergic hypersensitivity after beta-blocker withdrawal.

Authors:  P J Ross; M J Lewis; D J Sheridan; A H Henderson
Journal:  Br Heart J       Date:  1981-06

6.  Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized trial.

Authors:  K L Rice; J B Rubins; F Lebahn; C M Parenti; P G Duane; M Kuskowski; A M Joseph; D E Niewoehner
Journal:  Am J Respir Crit Care Med       Date:  2000-07       Impact factor: 21.405

Review 7.  Studies to reduce unnecessary medication use in frail older adults: a systematic review.

Authors:  Jennifer Tjia; Sarah J Velten; Carole Parsons; Sruthi Valluri; Becky A Briesacher
Journal:  Drugs Aging       Date:  2013-05       Impact factor: 3.923

8.  The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial.

Authors:  Clive Ballard; Maria Luisa Hanney; Megan Theodoulou; Simon Douglas; Rupert McShane; Katja Kossakowski; Randeep Gill; Edmund Juszczak; Ly-Mee Yu; Robin Jacoby
Journal:  Lancet Neurol       Date:  2009-01-08       Impact factor: 44.182

9.  Stopping antipsychotic drug therapy in demented nursing home patients: a randomized, placebo-controlled study--the Bergen District Nursing Home Study (BEDNURS).

Authors:  Sabine Ruths; Jørund Straand; Harald A Nygaard; Dag Aarsland
Journal:  Int J Geriatr Psychiatry       Date:  2008-09       Impact factor: 3.485

10.  The development and evaluation of an oncological palliative care deprescribing guideline: the 'OncPal deprescribing guideline'.

Authors:  Julian Lindsay; Michael Dooley; Jennifer Martin; Michael Fay; Alison Kearney; Mohsina Khatun; Michael Barras
Journal:  Support Care Cancer       Date:  2014-07-01       Impact factor: 3.603

View more
  4 in total

1.  Deprescribing trials: A focus on adverse drug withdrawal events.

Authors:  Joseph T Hanlon; Shelly L Gray
Journal:  J Am Geriatr Soc       Date:  2022-05-21       Impact factor: 7.538

2.  Appropriateness of care: from medication reconciliation to deprescribing.

Authors:  Maddalena Alessandra Wu; Carla Carnovale; Claudia Gabiati; Daniela Montori; Antonio Brucato
Journal:  Intern Emerg Med       Date:  2021-09-28       Impact factor: 3.397

3.  Methodological Challenges for Epidemiologic Studies of Deprescribing at the End of Life.

Authors:  Jennifer Tjia; Jennifer L Lund; Deborah S Mack; Attah Mbrah; Yiyang Yuan; Qiaoxi Chen; Seun Osundolire; Cara L McDermott
Journal:  Curr Epidemiol Rep       Date:  2021-04-23

4.  Direct-to-consumer strategies to promote deprescribing in primary care: a pilot study.

Authors:  Amy M Linsky; Nancy R Kressin; Kelly Stolzmann; Jacquelyn Pendergast; Amy K Rosen; Barbara G Bokhour; Steven R Simon
Journal:  BMC Prim Care       Date:  2022-03-22
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.